- Noah Medical is preparing a Hong Kong IPO to raise more than US$100 million, with a listing application planned as early as next year.
- The US-headquartered surgical robotics company plans to use a Hong Kong listing to support sales expansion across mainland China, including top-tier and emerging cities such as Hangzhou.
- China's drug regulator approved Noah Medical's equipment in November last year; the company is targeting Sir Run Run Shaw Hospital and says Hong Kong's Prince of Wales Hospital has purchased its equipment.
- The United States currently generates 90% of Noah Medical revenue, where its surgical robots have treated about 15,000 patients.
Quotes
“We want to expand our business in [mainland] China, and Hong Kong – as an international financial centre with a globally recognised stock exchange – is the natural choice for our listing”